NRx Pharmaceuticals, Inc. today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 11,576,911. This patent, issued to Glytech LLC, is exclusively licensed to NeuroRx, Inc., a wholly owned subsidiary of NRx, under the terms of a license agreement with Glytech through which NeuroRx has the sole rights to this and other patents, both U.S. and international.
depression
Feb. 22, 2023
NRx Pharmaceuticals Builds on Its Intellectual Property Foundation for Neuropsychiatric Conditions – Adds New U.S. Patent to Portfolio
Aug. 2, 2022
CEO Update on Recent Findings Related to Serotonin and its Role in Depression
In light of recent findings related to serotonin and its role in depression, investors have asked us to provide more specific information on the primary target addressed by D-cycloserine, a component of NRX-101.
Aug. 1, 2022
Scientific Update from NRx Pharmaceuticals Chief Scientist, Jonathan Javitt, MD, MPH
In light of recent findings related to serotonin and its role in depression, investors have asked us to provide more specific information on the primary target addressed by D-cycloserine, a component of NRX-101.